share_log

TG Therapeutics | 8-K: ® TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI (ublituximab-xiiy) Full Year Revenue Guidance

SEC ·  Nov 4, 2024 20:24
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more